Terns Pharmaceuticals, Inc. (TERN)
| Market Cap | 6.11B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -96.21M |
| Shares Out | 115.46M |
| EPS (ttm) | -1.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,286,072 |
| Open | 52.95 |
| Previous Close | 52.95 |
| Day's Range | 52.92 - 52.97 |
| 52-Week Range | 2.66 - 53.19 |
| Beta | -0.38 |
| Analysts | Buy |
| Price Target | 45.22 (-14.58%) |
| Earnings Date | May 14, 2026 |
About TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metaboli... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for TERN stock is "Buy." The 12-month stock price target is $45.22, which is a decrease of -14.58% from the latest price.
News
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
Designation for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase (CP) without the T315I mutation previously treated with tw...
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act o...
Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.
Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding share...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as...
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma
Merck said on Wednesday it would buy biotech Terns Pharma in a deal valued at up to $6.7 billion, as the drugmaker races to bolster its cancer pipeline ahead of the looming patent loss f...
Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns
The drugmaker has been seeking to bolster its pipeline as its top-selling drug, Keytruda, is set to lose patent protection.
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Terns' lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor c urrently in Phase 1/2 development for certain patients with CML
Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports
Merck is nearing a roughly $6 billion all-cash deal to buy biotech firm Terns Pharma , the Financial Times reported on Tuesday, citing people familiar with the matter.
Terns Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026
TERN-701 demonstrated unprecedented efficacy and a clean safety profile in CML, outperforming current therapies, including in refractory and mutation-positive patients. Dose selection and pivotal study plans are advancing, with funding secured through commercialization.
Terns Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
The company has transitioned to focus on CML with TERN-701, showing strong efficacy and safety in third-line-plus patients, outperforming current allosteric competitors. Market opportunity is significant, with pivotal studies progressing and plans for frontline trials.
Terns Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Promising Phase I data for TERN-701 in CML show high efficacy and favorable safety, with ongoing dose expansion and pivotal trial planning. The drug demonstrates strong differentiation from competitors, including activity against resistant mutations, and is positioned for both frontline and second-line use.
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior ...
Terns Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
TERN-701 showed unprecedented efficacy and safety in refractory CML, with 75% MMR at key doses and no dose-limiting toxicities. Pivotal trials and regulatory steps are planned for 2026, supported by $1B in cash and a strong market opportunity.
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference
CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and ...
Terns CEO Amy Burroughs talks cancer drug trial win
Amy Burroughs, Terns Pharmaceuticals CEO, joins 'Fast Money' to talk its latest cancer drug data
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its prev...
Terns Announces Pricing of Upsized $650 Million Public Offering
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsi...
Cancer Study Buoys These Small Biotechs
Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of leukemia patients treated with the firm's once-daily pill.
Terns Announces Proposed Public Offering
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has commenced a...
Terns Pharmaceuticals Transcript: Study Update
TERN-701 demonstrated unprecedented efficacy in heavily pretreated CML patients, achieving 75% MMR and 36% DMR at 24 weeks at higher doses, with a favorable safety profile and no significant pancreatic or blood pressure toxicity. These results support its potential as a best-in-disease therapy for both frontline and second-line CML.